Nabriva Therapeutics raises $120M for drugs that attack antibiotic resistant bacteria that cause pneumonia
Transatlantic antibiotics maker Nabriva Therapeutics just raised an enormous swath of cash – it just closed a $120 million Series B round to treat serious and highly resistant bacterial infections. It’s validation for a largely underused class of antibiotics – pleuromutilins – and a step in the direction to address global antibiotic resistance. The first, $50 million tranche […]